Bioethicists of life extension stories

Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 20262 sources

Apr 14, 2026

FDA Pushes Drugmakers to Report Missing Clinical Trial Results

FDA officials revealed that nearly 30% of clinical trial studies highly likely to fall under mandatory reporting requirements failed to submit results, prompting new enforcement efforts to improve transparency.

Apr 14, 20261 source

Apr 10, 2026

FDA Rejects Replimune's Skin Cancer Drug for Second Time

The FDA has rejected Replimune's cancer drug candidate for the second time, a treatment that had become a flashpoint at the agency over approval standards.

Apr 10, 20261 source

Apr 7, 2026

Merck's Experimental HIV Prevention Pill Could Be Manufactured for Under $5 Annually, Researchers Say

Researchers published findings that Merck's experimental HIV prevention pill could be produced for less than $5 per year, urging the company to urgently begin licensing generic production to improve global access.

Apr 7, 20261 source

Apr 2, 2026

FDA Approves Eli Lilly's Obesity Pill, Setting Up Competition with Novo Nordisk

The FDA has approved Eli Lilly's oral obesity medication, marking a significant development in the weight-loss drug market and positioning it for direct competition against Novo Nordisk's Wegovy pill.

Apr 2, 20261 source

Apr 1, 2026

Doctors Without Borders Accuses Gilead of Refusing to Sell HIV Prevention Drug Lenacapavir

Doctors Without Borders publicly criticized Gilead Sciences as 'unconscionable' after the company refused to provide even a limited supply of its HIV prevention drug lenacapavir following months of negotiations.

Apr 1, 20262 sources

Top claims

▪The compassionate use pathway allows patients with serious and immediately life-threatening medical issues to access experimental treatments
▪Eli Lilly and the FDA granted one person access to the experimental drug retatrutide through the FDA's "compassionate use" program
▪The decision to grant access drew the interest of top health officials, suggesting the recipient was well-connected

Subtopics

Pharma4 Drug Approval and Clinical Trials3 AI policy2 AI regulation & lawsuits2 Infectious Disease and Outbreaks2 Lifestyle, Wellness and Nutrition2 Preventive longevity physicians2 Supplement regulation2 Weight management2 Clinical trials1 Eli Lilly1 GLP-1 medications1 Retatrutide1 US health policy & drug pricing1

Related timelines